Gene sequencing company Illumina will be acquiring Jeff Bezos and Bill Gates-backed cancer screening startup GRAIL. Illumina will be paying $8 billion in cash and stock to buy the startup. Under the terms of the agreement, GRAIL stockholders, including Illumina, will receive $3.5 billion in cash and $4.5 billion in shares of Illumina common stock.